hypogonadism; testosterone; cvd; fda

  1. madman

    John P. Mulhall, MD, shares his reaction to the FDA’s testosterone labeling changes

    * He added, “It is my hope that the AUA will, in short order, go back and change that statement, so that we now have guideline-based instructions to physicians that will say, you are now allowed to say to patients that testosterone therapy is not associated with major adverse cardiovascular...
Back
Top